A

Amolyt Pharma

Biotech & Life Sciences · Écully, France · Founded 2014

Amolyt Pharma, a clinical-stage biotechnology company, was established in 2019 through a collaborative effort between its founding scientists, Dr. Thierry Abribat, and life sciences venture capital firms Sofinnova Partners and Bpifrance. The company is strategically focused on developing therapeutic peptides for rare endocrine and related diseases. Dr. Abribat, serving as the Chief Executive Officer, brings extensive experience from his previous roles, including founding and leading Alize Pharma and holding positions at Ambrilia Biopharma, all of which were centered on metabolic and endocrine disorders, directly aligning with Amolyt's mission. The company's business model centers on advancing its pipeline of specialized treatments through clinical trials to address unmet needs in the rare endocrine disease market. Its primary client base consists of patients suffering from these specific conditions, with the ultimate goal of commercializing its therapies for healthcare providers and systems globally. Amolyt Pharma operates within the specialty biopharmaceutical sector, a market characterized by high barriers to entry due to rigorous regulatory requirements and the need for specialized scientific expertise. The firm has secured substantial funding from a syndicate of international investors, including Novo Holdings, an entity with a significant stake that has supported its research and development efforts. Amolyt Pharma's lead product candidate is eneboparatide (formerly AZP-3601), a long-acting parathyroid hormone (PTH) analog designed for the treatment of hypoparathyroidism. This condition is characterized by low levels of PTH, leading to decreased calcium and elevated phosphorus levels in the blood. Eneboparatide aims to provide a more stable and sustained regulation of calcium levels, potentially reducing the need for daily calcium and vitamin D supplements and mitigating long-term complications associated with the disease. Another key asset in its portfolio is AZP-3813, a peptide antagonist for the growth hormone receptor, being developed as a potential treatment for acromegaly, a disorder resulting from excess growth hormone. In a significant milestone for the company, Amolyt Pharma entered into a definitive agreement to be acquired by AstraZeneca in March 2024 for a total consideration of up to $1.05 billion. This acquisition underscores the perceived value of Amolyt's therapeutic pipeline and provides a clear path toward potential global commercialization. Keywords: rare endocrine diseases, hypoparathyroidism, acromegaly, therapeutic peptides, eneboparatide, clinical-stage biotechnology, PTH analog, orphan drugs, endocrinology, biopharmaceutical